Lanifibranor

Lanifibranor
Identifiers
	IUPAC name 4-[1-(1,3-Benzothiazol-6-ylsulfonyl)-5-chloroindol-2-yl]butanoic acid;
CAS Number	927961-18-0;
PubChem CID	68677842;
DrugBank	DB14801;
ChemSpider	58828074;
UNII	28Q8AG0PYL;
ChEMBL	ChEMBL4091374;
ECHA InfoCard	100.218.645
Chemical and physical data
Formula	C19H15ClN2O4S2
Molar mass	434.91 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1=CC2=C(C=C1S(=O)(=O)N3C4=C(C=C(C=C4)Cl)C=C3CCCC(=O)O)SC=N2;
	InChI InChI=1S/C19H15ClN2O4S2/c20-13-4-7-17-12(8-13)9-14(2-1-3-19(23)24)22(17)28(25,26)15-5-6-16-18(10-15)27-11-21-16/h4-11H,1-3H2,(H,23,24); Key:OQDQIFQRNZIEEJ-UHFFFAOYSA-N;

Lanifibranor is a pan-PPAR (peroxisome proliferator-activated receptor) receptor agonist and is the first medication that targets PPAR-alpha, PPAR-beta, and PPAR-gamma simultaneously.^[1]^[2]^[3] As of 2023, it is in a phase III trial for nonalcoholic steatohepatitis; its advantage over other drugs that are in phase III trials for the same condition is that it has shown improvements in both steatohepatitis and fibrosis.^[4]

Quick Facts Identifiers, CAS Number ...

References